Loading company…
Mekonos develops microfluidic systems for targeted ex vivo gene engineering and biopharmaceutical research.
Mekonos develops microfluidic technology and a system-on-a-chip for gene engineering and biological research. Its solutions are intended for pharmaceutical companies and research institutions working on gene therapies and drug development. Founded in 2017 and based in San Francisco, it raised USD 24.98 mn in Series A funding in October 2021.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in